A Stark Surge in Sexually Transmitted Infections Floods Europe: Confronting a Decade of Neglected Epidemics
Across the European Union and European Economic Area (EU/EEA), 2024 has marked an alarming milestone in the epidemiology of bacterial sexually transmitted infections (STIs). Latest data from the European Centre for Disease Prevention and Control (ECDC) unveil an unprecedented surge in cases of gonorrhoea, syphilis—including congenital syphilis—as well as sustained transmissions of other bacterial STIs. This disturbing trend, accelerating over the last decade, reflects a multifaceted public health crisis that threatens to undermine progress made in STI control, while also revealing critical gaps in current prevention, testing, and treatment strategies.
Among the forefront offenders of this resurgence, gonorrhoea cases registered an astonishing height of 106,331 in 2024, amounting to a dramatic 303% increase since 2015. This increase far outpaces population growth and hints at persistent and widespread transmission. Similarly, syphilis cases have more than doubled to a current tally of 45,577, with congenital syphilis—an infection transmitted from mother to child during pregnancy—nearly doubling from 78 cases in 2023 to 140 in 2024 across 14 reporting nations. Chlamydia remains the most reported STI, with 213,443 cases representing the ongoing challenge presented by asymptomatic infections. Lymphogranuloma venereum (LGV), though less prevalent, also demonstrates continuous dissemination with 3,490 cases documented.
The epidemiological patterns uncovered paint a grim picture in which untreated bacterial STIs lay the foundation for severe health complications. Syphilis, for instance, if unchecked, can progress to involve the cardiovascular system or central nervous system, causing life-threatening sequelae. Similarly, gonorrhoea and chlamydia, when untreated, are implicated in chronic pelvic pain, infertility, and heightened HIV transmission risk. Crucially, congenital syphilis, stemming from insufficient maternal screening and treatment, exposes newborns to devastating lifelong disabilities or death, underscoring an urgent call to enhance antenatal care infrastructure.
The drivers of this STI resurgence are intricately linked to evolving behavioral, social, and systemic factors. Men who have sex with men represent the cohort most disproportionately affected, bearing the brunt of steep, long-term increments in gonorrhoea and syphilis cases. For heterosexual populations, particularly women of reproductive age, rising syphilis incidences precipitate the concerning rise in congenital cases. These divergent transmission dynamics underscore the heterogeneity of the epidemic and the need for tailored interventions specific to sexual orientation, gender, and age strata.
Beyond behavioral risk factors, structural hindrances exacerbate the epidemic. Data expose widely variable access to STI testing and treatment services, with 13 out of 29 reporting countries continuing to impose out-of-pocket fees for basic STI diagnostics. Such financial barriers dissuade individuals from seeking timely care, fostering continued transmission chains. Additionally, many countries operate national prevention strategies that are outdated and fail to incorporate the post-COVID-19 behavioral landscape, including changes in social interactions and healthcare utilization patterns.
ECDC’s recent monitoring report on congenital syphilis reveals critical missed opportunities as well. Gaps in antenatal screening—ranging from incomplete coverage, lack of follow-up testing, to delayed or insufficient treatment—perpetuate maternal infections and vertical transmission. Prompt identification and stage-specific treatment of syphilis during pregnancy remain paramount to interrupting transmission to the fetus and mitigating long-term adverse outcomes.
Interestingly, the European health authorities have embraced pharmaceutical innovation to enhance STI prevention. A notable example is the January 2026 ECDC guidance on doxycycline post-exposure prophylaxis (doxy-PEP), which offers a promising adjunct to existing prevention for high-exposure groups. However, its application is carefully circumscribed due to rising antimicrobial resistance in gonorrhoea strains. The indiscriminate or widespread use of doxycycline risks accelerating resistance further, potentially nullifying future treatment options. Thus, doxy-PEP is advised only under the guidance of healthcare providers for select high-risk individuals.
The convergence of these complexities signals an urgent call for a paradigm shift in STI public health responses. In order to reverse backsliding trends, European countries must prioritize expanded and equitable access to STI prevention and testing services, rapid initiation of effective treatment, and meticulous partner notification systems to interrupt transmission networks. Updating national strategies to reflect contemporary epidemiological and behavioral realities is equally vital.
Detecting and counteracting STI transmission also necessitate robust and real-time surveillance systems. Enhanced data collection, integration, and reporting capabilities will inform targeted, evidence-based interventions and facilitate the evaluation of public health impact over time. Without such infrastructure, the silent spread of infections could accelerate unchecked, exacerbating the burden of disease.
Fundamentally, public health messaging plays a crucial role in stemming STI spread. Clear communication encouraging condom use with new or multiple partners, awareness of symptoms such as genital ulcers, abnormal discharge, or pain, and timely healthcare engagement remain simple yet effective preventative measures. Tailored education campaigns that resonate with diverse population groups—including men who have sex with men and women of reproductive age—are indispensable.
The escalating incidence of bacterial STIs heralds a looming public health emergency, whereby lethargy in policy, prevention, and care infrastructure will translate into enduring societal costs. The decade-long ascent culminating in record 2024 figures should serve as an unambiguous wake-up call. Only through coordinated, well-resourced, and scientifically grounded interventions can Europe hope to reclaim control over these largely preventable infections.
Preventing the continued rise of gonorrhoea, syphilis, chlamydia, and LGV is not only a matter of individual health, but also an essential component of safeguarding population-wide well-being, reproductive health, and health equity. As antimicrobial resistance threatens to complicate therapeutic landscapes, the stakes rise further. A proactive, comprehensive response transcending national boundaries and integrating behavioral, clinical, and public health domains is urgent and non-negotiable.
The science is unequivocal and the mandate clear: intensify testing, treatment, surveillance, education, and prevention in an era marked by rapidly evolving epidemiology and microbial resilience. The cost of inaction is measured not only in rising case numbers but in lives irreversibly altered. Europe stands at a critical crossroads in its fight against bacterial STIs — the next steps will define the trajectory of these epidemics for decades to come.
Subject of Research: Epidemiology and Public Health Response to Bacterial Sexually Transmitted Infections in Europe
Article Title: Europe Confronts a Decade-Long Surge in Bacterial STIs with Historic Case Numbers in 2024
News Publication Date: 2024
Web References:
– https://www.ecdc.europa.eu/en/news-events/rising-stis-europe-report-finds-critical-gaps-testing-and-prevention-policies
– https://www.ecdc.europa.eu/en/publications-data/chlamydia-annual-epidemiological-report-2024
– https://www.ecdc.europa.eu/en/news-events/ecdc-issues-guidance-doxycycline-sti-prevention
Image Credits: National Institute of Allergy and Infectious Diseases, National Institutes of Health
Keywords: Sexually transmitted infections, gonorrhoea, syphilis, congenital syphilis, chlamydia, lymphogranuloma venereum, bacterial STIs, antimicrobial resistance, doxycycline post-exposure prophylaxis, public health, epidemiology, European Centre for Disease Prevention and Control, STI prevention, reproductive health, infectious diseases, surveillance
Tags: bacterial sexually transmitted infections in Europechallenges in STI treatment Europechlamydia asymptomatic infection ratescongenital syphilis increase EuropeECDC bacterial STI data 2024European STI epidemiology trendsgonorrhoea surge 2024lymphogranuloma venereum outbreaks Europerise in congenital syphilis casesSTI prevention testing gapsSTI public health crisis Europesyphilis epidemic in EU/EEA
